Shanghai Henlius Biotech (HKG:2696) signed a collaboration and license agreement with Amberstone Biosciences for the worldwide research, development, manufacturing and commercialization of two T cell engager (TCE) products based on Amberstone's T-MATE technology platform.
Henlius will pay Amberstone $4 million upfront, plus up to $232.2 million in research, development and regulatory milestones and up to $652 million in sales milestones, according to a Wednesday Hong Kong bourse filing.
Amberstone will also receive royalties at a single-digit percentage of annual net sales.